Literature DB >> 24436519

Irreversible electroporation of hepatic malignancy.

Govindarajan Narayanan1, Tatiana Froud1, Rekhaben Suthar1, Katuska Barbery1.   

Abstract

Hepatocellular carcinoma (HCC) is a worldwide problem of epidemic proportions, best treated in a multidisciplinary setting. Major advances have been made in all specialties that manage patients with HCC, with surgical options at one end of the spectrum and palliative chemotherapy on the other, and the vast majority of patients require the involvement and expertise of interventional oncology. Several ablative and transarterial technologies are currently available. Irreversible electroporation (IRE) is a new ablative technology that uses high-voltage, low-energy DC current to create nanopores in the cell membrane, disrupting the homeostasis mechanism and inducing cell death by initiating apoptosis. This article discusses the evolution of IRE as well as its safety and efficacy in the context of other ablative therapies in the treatment of hepatic malignancies.

Entities:  

Keywords:  NanoKnife; apoptosis; hepatocellular carcinoma (HCC) ablation; irreversible electroporation (IRE)

Year:  2013        PMID: 24436519      PMCID: PMC3700786          DOI: 10.1055/s-0033-1333655

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  27 in total

1.  Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations.

Authors:  Takuma Teratani; Haruhiko Yoshida; Shuichiro Shiina; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Norio Mine; Yuji Kondo; Takao Kawabe; Masao Omata
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

2.  Ablation of perivascular hepatic malignant tumors with irreversible electroporation.

Authors:  T Peter Kingham; Ami M Karkar; Michael I D'Angelica; Peter J Allen; Ronald P Dematteo; George I Getrajdman; Constantinos T Sofocleous; Stephen B Solomon; William R Jarnagin; Yuman Fong
Journal:  J Am Coll Surg       Date:  2012-06-16       Impact factor: 6.113

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 4.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

5.  Pain analysis in patients with hepatocellular carcinoma: irreversible electroporation versus radiofrequency ablation-initial observations.

Authors:  Govindarajan Narayanan; Tatiana Froud; Kaming Lo; Katuska J Barbery; Evelyn Perez-Rojas; Jose Yrizarry
Journal:  Cardiovasc Intervent Radiol       Date:  2012-06-30       Impact factor: 2.740

6.  Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study.

Authors:  J A Davila; R O Morgan; Y Shaib; K A McGlynn; H B El-Serag
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma.

Authors:  Govindarajan Narayanan; Peter J Hosein; Geetika Arora; Katuzka J Barbery; Tatiana Froud; Alan S Livingstone; Dido Franceschi; Caio M Rocha Lima; Jose Yrizarry
Journal:  J Vasc Interv Radiol       Date:  2012-12       Impact factor: 3.464

Review 9.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.

Authors:  Yun Ku Cho; Jae Kyun Kim; Mi Young Kim; Hyunchul Rhim; Joon Koo Han
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

10.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more
  11 in total

Review 1.  Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System.

Authors:  Sonal Krishan; Radha K Dhiman; Navin Kalra; Raju Sharma; Sanjay S Baijal; Anil Arora; Ajay Gulati; Anu Eapan; Ashish Verma; Shyam Keshava; Amar Mukund; S Deva; Ravi Chaudhary; Karthick Ganesan; Sunil Taneja; Ujjwal Gorsi; Shivanand Gamanagatti; Kumble S Madhusudan; Pankaj Puri; Shallini Govil; Manav Wadhavan; Sanjiv Saigal; Ashish Kumar; Shallini Thapar; Ajay Duseja; Neeraj Saraf; Anubhav Khandelwal; Sumit Mukhopadyay; Ajay Gulati; Nitin Shetty; Nipun Verma
Journal:  J Clin Exp Hepatol       Date:  2019-08-06

2.  Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation: feasibility, safety and efficacy.

Authors:  Maria Paola Belfiore; Alfonso Reginelli; Nicola Maggialetti; Mattia Carbone; Sabrina Giovine; Antonella Laporta; Fabrizio Urraro; Valerio Nardone; Roberta Grassi; Salvatore Cappabianca; Luca Brunese
Journal:  Med Oncol       Date:  2020-04-09       Impact factor: 3.064

3.  Ultrasound-guided percutaneous irreversible electroporation of hepatic and abdominal tumors not eligible for surgery or thermal ablation: a western report on safety and efficacy.

Authors:  A Giorgio; F Amendola; A Calvanese; E Ingenito; B Santoro; P Gatti; E Ciracì; P Matteucci; V Giorgio
Journal:  J Ultrasound       Date:  2019-03-06

4.  In vivo evaluation of bronchial injury of irreversible electroporation in a porcine lung ablation model by using laboratory, pathological, and CT findings.

Authors:  Jun-Hui Sun; Tong-Yin Zhu; Xin-Hua Chen; Chun-Hui Nie; Zhi-Gang Ren; Guan-Hui Zhou; Tan-Yang Zhou; Sheng-Yong Yin; Zhi-Yi Peng; Li-Ming Wu; Xiong-Xin Zhang; Wei-Lin Wang; Shu-Sen Zheng
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

5.  Using non-thermal irreversible electroporation to create an in vivo niche for exogenous cell engraftment.

Authors:  Tammy T Chang; Vivian X Zhou; Boris Rubinsky
Journal:  Biotechniques       Date:  2017-05-01       Impact factor: 1.993

6.  Advances and Future Directions in the Treatment of Hepatocellular Carcinoma.

Authors:  Ashil J Gosalia; Paul Martin; Patricia D Jones
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

7.  Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC).

Authors:  Neal Bhutiani; Prejesh Philips; Charles R Scoggins; Kelly M McMasters; Melissa H Potts; Robert C G Martin
Journal:  HPB (Oxford)       Date:  2016-05-01       Impact factor: 3.647

Review 8.  Irreversible Electroporation: A Novel Ultrasound-guided Modality for Non-thermal Tumor Ablation.

Authors:  Chih-Yang Hsiao; Kai-Wen Huang
Journal:  J Med Ultrasound       Date:  2017-10-06

9.  Electroporation of the Liver: More Than 2 Concurrently Active, Curved Electrodes Allow New Concepts for Irreversible Electroporation and Electrochemotherapy.

Authors:  Andreas Ritter; Philipp Bruners; Peter Isfort; Alexandra Barabasch; Joachim Pfeffer; Jula Schmitz; Federico Pedersoli; Martin Baumann
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

10.  Toward a clinical real time tissue ablation technology: combining electroporation and electrolysis (E2).

Authors:  Enric Guenther; Nina Klein; Paul Mikus; Florin Botea; Mihail Pautov; Franco Lugnani; Matteo Macchioro; Irinel Popescu; Michael K Stehling; Boris Rubinsky
Journal:  PeerJ       Date:  2020-01-20       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.